tiprankstipranks
Advertisement
Advertisement

Organogenesis Names Patrick McGuire Chief Accounting Officer

Story Highlights
  • Organogenesis appointed Patrick McGuire as Chief Accounting Officer on February 18, 2026.
  • McGuire’s promotion adjusts his salary while David Francisco remains Chief Financial Officer.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Organogenesis Names Patrick McGuire Chief Accounting Officer

Claim 55% Off TipRanks

Organogenesis Holdings ( (ORGO) ) just unveiled an update.

On February 18, 2026, Organogenesis Holdings Inc. appointed Patrick McGuire, 40, as Chief Accounting Officer and principal accounting officer, effective immediately, elevating him from his prior role as Vice President, Corporate Controller. McGuire, a licensed CPA with extensive tenure at PricewaterhouseCoopers and prior controller experience at Cynosure, will receive an increased annual base salary of $345,000, while former principal accounting officer David Francisco will continue in his role as Chief Financial Officer and principal financial officer, maintaining continuity in the company’s broader financial leadership structure.

The most recent analyst rating on (ORGO) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Organogenesis Holdings stock, see the ORGO Stock Forecast page.

Spark’s Take on ORGO Stock

According to Spark, TipRanks’ AI Analyst, ORGO is a Neutral.

Overall score is held back mainly by weak profitability and negative operating/free cash flow despite a strong balance sheet. Recent technicals are moderately supportive, and the latest earnings call showed strong revenue/EBITDA execution and raised guidance, but clinical/regulatory timing issues and the cash decline add meaningful risk. Valuation is also less supportive due to the negative P/E.

To see Spark’s full report on ORGO stock, click here.

More about Organogenesis Holdings

Organogenesis Holdings Inc. is a regenerative medicine company operating in the broader pharmaceutical, life sciences and medical device ecosystem. The company focuses on advanced therapies and related products, supported by a financial leadership team with experience across these healthcare sectors, reflecting its positioning within specialized medical markets.

Average Trading Volume: 1,079,176

Technical Sentiment Signal: Sell

Current Market Cap: $487.3M

Learn more about ORGO stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1